446 related articles for article (PubMed ID: 30149002)
21. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib.
Chen W; Li Z; Liu H; Jiang S; Wang G; Sun L; Li J; Wang X; Yu S; Huang J; Dong Y
Cell Death Dis; 2020 Mar; 11(3):198. PubMed ID: 32251287
[TBL] [Abstract][Full Text] [Related]
23. Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.
Zhang LY; Huang JS; Pi ZM; Yu MY
Int J Clin Exp Pathol; 2015; 8(9):11340-7. PubMed ID: 26617858
[TBL] [Abstract][Full Text] [Related]
24. MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.
Gao X; Shen K; Wang C; Ling J; Wang H; Fang Y; Shi Y; Hou Y; Qin J; Sun Y; Qin X
Acta Biochim Biophys Sin (Shanghai); 2014 Jan; 46(1):72-5. PubMed ID: 24217767
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
Sakurama K; Noma K; Takaoka M; Tomono Y; Watanabe N; Hatakeyama S; Ohmori O; Hirota S; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Tanaka N; Naomoto Y
Mol Cancer Ther; 2009 Jan; 8(1):127-34. PubMed ID: 19139121
[TBL] [Abstract][Full Text] [Related]
26. Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.
Vitiello GA; Medina BD; Zeng S; Bowler TG; Zhang JQ; Loo JK; Param NJ; Liu M; Moral AJ; Zhao JN; Rossi F; Antonescu CR; Balachandran VP; Cross JR; DeMatteo RP
Clin Cancer Res; 2018 Feb; 24(4):972-984. PubMed ID: 29246941
[No Abstract] [Full Text] [Related]
27. miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT.
Wang Y; Li J; Kuang D; Wang X; Zhu Y; Xu S; Chen Y; Cheng H; Zhao Q; Duan Y; Wang G
Cell Commun Signal; 2018 Apr; 16(1):16. PubMed ID: 29661252
[TBL] [Abstract][Full Text] [Related]
28. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.
Javidi-Sharifi N; Traer E; Martinez J; Gupta A; Taguchi T; Dunlap J; Heinrich MC; Corless CL; Rubin BP; Druker BJ; Tyner JW
Cancer Res; 2015 Mar; 75(5):880-91. PubMed ID: 25432174
[TBL] [Abstract][Full Text] [Related]
29. New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.
Takahashi T; Serada S; Ako M; Fujimoto M; Miyazaki Y; Nakatsuka R; Ikezoe T; Yokoyama A; Taguchi T; Shimada K; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y; Naka T; Nishida T
Int J Cancer; 2013 Dec; 133(11):2737-43. PubMed ID: 23716303
[TBL] [Abstract][Full Text] [Related]
30. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
[TBL] [Abstract][Full Text] [Related]
31. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
Kaymaz BT; Günel NS; Ceyhan M; Çetintaş VB; Özel B; Yandım MK; Kıpçak S; Aktan Ç; Gökbulut AA; Baran Y; Can BK
Tumour Biol; 2015 Sep; 36(10):7915-27. PubMed ID: 25953263
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
Sako H; Fukuda K; Saikawa Y; Nakamura R; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Ohmori T; Kitagawa Y
PLoS One; 2014; 9(9):e107613. PubMed ID: 25221952
[TBL] [Abstract][Full Text] [Related]
34. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P
Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595
[TBL] [Abstract][Full Text] [Related]
35. Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.
Falkenhorst J; Grunewald S; Mühlenberg T; Marino-Enriquez A; Reis AC; Corless C; Heinrich M; Treckmann J; Podleska LE; Schuler M; Fletcher JA; Bauer S
Oncotarget; 2016 Jul; 7(27):41390-41403. PubMed ID: 27167336
[TBL] [Abstract][Full Text] [Related]
36. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors.
Hsueh YS; Chang HH; Shan YS; Sun HS; Fletcher JA; Li CF; Chen LT
Oncogene; 2019 Sep; 38(38):6550-6565. PubMed ID: 31363162
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E
Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413
[TBL] [Abstract][Full Text] [Related]
38. miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers.
Nannini M; Ravegnini G; Angelini S; Astolfi A; Biasco G; Pantaleo MA
Epigenomics; 2015; 7(6):1033-49. PubMed ID: 26447534
[TBL] [Abstract][Full Text] [Related]
39. The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.
Kinsella P; Greene LM; Bright SA; Pollock JK; Butini S; Campiani G; Bauer S; Williams DC; Zisterer DM
Invest New Drugs; 2016 Apr; 34(2):159-67. PubMed ID: 26885657
[TBL] [Abstract][Full Text] [Related]
40. KIT
Banerjee S; Yoon H; Ting S; Tang CM; Yebra M; Wenzel AT; Yeerna H; Mesirov JP; Wechsler-Reya RJ; Tamayo P; Sicklick JK
Mol Cancer Ther; 2021 Oct; 20(10):2035-2048. PubMed ID: 34376580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
